Trial · NCT02080624
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 6 | Baseline, Week 6 | Change Outcome Measure |
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 12 | Baseline, Week 12 | Change Outcome Measure |
| Primary | Change from baseline in morphologic, chromatographic and spectrometric scores at week 18 | Baseline, Week 18 | Change Outcome Measure |
| Primary | Histological response at 12 weeks. | 12 weeks | Efficacy Outcome Measure |
| Secondary | Adverse events at baseline | At the beginning of the intervention | |
| Secondary | Adverse events at 6 weeks | 6 weeks after the beginning of the intervention | |
| Secondary | Adverse events at 12 weeks | 12 weeks after the beginning of the intervention | |
| Secondary | Adverse events at 18 weeks | 18 weeks after the beginning of the intervention | |
| Secondary | Total blood cholesterol level (mg/dL) at baseline. | At the beginning of the intervention | |
| Secondary | Total blood cholesterol level (mg/dL) at 6 weeks. | 6 weeks after the beginning of the intervention | |
| Secondary | Blood concentration of triglycerides (mg/dL) at baseline. | At the beginning of the intervention | |
| Secondary | Blood concentration of triglycerides (mg/dL) at 6 weeks. | At 6 weeks after the beginning of the intervention | |
| Secondary | Blood concentration of hemoglobin (g/dL) at baseline. | At the beginning of the intervention | |
| Secondary | Blood concentration of hemoglobin (g/dL) at 6 weeks. | At 6 weeks after the beginning of the intervention | |
| Secondary | Blood count of leukocytes (number of cells/mL) at baseline. | At the beginning of the intervention. | |
| Secondary | Blood count of leukocytes (number of cells/mL) at 6 weeks. | At 6 weeks after the beginning of the intervention. | |
| Secondary | Blood platelet count (number of platelets/mL) at baseline. | At the beginning of the intervention. | |
| Secondary | Blood concentration of rapamycin (ng/ml) at baseline. | At the beginning of the intervention. | |
| Secondary | Blood concentration of rapamycin (ng/ml) at 6 weeks. | At 6 weeks after the beginning of the intervention. | |
| Secondary | Blood platelet count (number of platelets/mL) at 6 weeks. | At 6 weeks after the beginning of the intervention. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02080624/registered